FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006721081> ?p ?o ?g. }

• W2006721081 endingPage "622" @default.
• W2006721081 startingPage "614" @default.
• W2006721081 abstract "Background: The trifunctional antibody ertumaxomab bivalently targets the human epidermal growth factor receptor 2 (Her2) on epithelial (tumor) cells and the T cell specific CD3 antigen, and its Fc region is selectively recognized by Fcγ type I/III receptor-positive immune cells. As a trifunctional immunoglobulin, ertumaxomab therefore not only targets Her2 on cancer cells, but also triggers immunological effector mechanisms mediated by T and accessory cells (e.g., macrophages, dendritic cells, natural killer cells). Whether molecular effects, however, might contribute to the cellular antitumor efficiency of ertumaxomab are largely unknown. Methods: Potential molecular effects of ertumaxomab on Her2-overexpressing BT474 and SK-BR-3 breast cancer cells were evaluated. The dissociation constant Kd of ertumaxomab was calculated from titration curves that were recorded by flow cytometry. Treatment-induced changes in Her2 homodimerization were determined by flow cytometric fluorescence resonance energy transfer measurements on a cell-by-cell basis. Potential activation / deactivation of Her2, ERK1/2, AKT and STAT3 were analyzed by western blotting, Immunochemistry and immunofluorescent cell staining. Results: The Kd of ertumaxomab for Her2-binding was determined at 265 nM and the ertumaxomab binding epitope was found to not overlap with that of the therapeutic anti-Her2 monoclonal antibodies trastuzumab and pertuzumab. Ertumaxomab caused an increase in Her2 phosphorylation at higher antibody concentrations, but changed neither the rate of Her2-homodimerization /-phosphorylation nor the activation state of key downstream signaling proteins analyzed. Conclusions: The unique mode of action of ertumaxomab, which relies more on activation of immune-mediated mechanisms against tumor cells compared with currently available therapeutic antibodies for breast cancer treatment, suggests that modular or sequential treatment with the trifunctional bivalent antibody might complement the therapeutic activity of other anti-Her2/anti-ErbB receptor reagents." @default.
• W2006721081 created "2016-06-24" @default.
• W2006721081 creator A5036428735 @default.
• W2006721081 creator A5044763291 @default.
• W2006721081 creator A5051464063 @default.
• W2006721081 creator A5084753156 @default.
• W2006721081 date "2012-09-01" @default.
• W2006721081 modified "2023-10-05" @default.
• W2006721081 title "Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling" @default.
• W2006721081 cites W1603672218 @default.
• W2006721081 cites W1918654887 @default.
• W2006721081 cites W1964321121 @default.
• W2006721081 cites W1969602144 @default.
• W2006721081 cites W1971267920 @default.
• W2006721081 cites W1972193434 @default.
• W2006721081 cites W1972848082 @default.
• W2006721081 cites W1985620074 @default.
• W2006721081 cites W1998297552 @default.
• W2006721081 cites W2002820833 @default.
• W2006721081 cites W2004759810 @default.
• W2006721081 cites W2012634952 @default.
• W2006721081 cites W2014457594 @default.
• W2006721081 cites W2019182965 @default.
• W2006721081 cites W2022554477 @default.
• W2006721081 cites W2024651005 @default.
• W2006721081 cites W2025307506 @default.
• W2006721081 cites W2026531155 @default.
• W2006721081 cites W2034091339 @default.
• W2006721081 cites W2036740994 @default.
• W2006721081 cites W2042313745 @default.
• W2006721081 cites W2046276878 @default.
• W2006721081 cites W2053779290 @default.
• W2006721081 cites W2053848912 @default.
• W2006721081 cites W2056743609 @default.
• W2006721081 cites W2068281228 @default.
• W2006721081 cites W2074430405 @default.
• W2006721081 cites W2075302864 @default.
• W2006721081 cites W2079078036 @default.
• W2006721081 cites W2085560694 @default.
• W2006721081 cites W2097692168 @default.
• W2006721081 cites W2098934164 @default.
• W2006721081 cites W2103364597 @default.
• W2006721081 cites W2104239861 @default.
• W2006721081 cites W2105349448 @default.
• W2006721081 cites W2116295027 @default.
• W2006721081 cites W2118371851 @default.
• W2006721081 cites W2123591186 @default.
• W2006721081 cites W2133519534 @default.
• W2006721081 cites W2139135964 @default.
• W2006721081 cites W2141592427 @default.
• W2006721081 cites W2151464858 @default.
• W2006721081 cites W2165003903 @default.
• W2006721081 cites W2166199281 @default.
• W2006721081 cites W2332928500 @default.
• W2006721081 doi "https://doi.org/10.4161/mabs.21003" @default.
• W2006721081 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3499302" @default.
• W2006721081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22820509" @default.
• W2006721081 hasPublicationYear "2012" @default.
• W2006721081 type Work @default.
• W2006721081 sameAs 2006721081 @default.
• W2006721081 citedByCount "12" @default.
• W2006721081 countsByYear W20067210812014 @default.
• W2006721081 countsByYear W20067210812015 @default.
• W2006721081 countsByYear W20067210812016 @default.
• W2006721081 countsByYear W20067210812017 @default.
• W2006721081 countsByYear W20067210812019 @default.
• W2006721081 countsByYear W20067210812021 @default.
• W2006721081 crossrefType "journal-article" @default.
• W2006721081 hasAuthorship W2006721081A5036428735 @default.
• W2006721081 hasAuthorship W2006721081A5044763291 @default.
• W2006721081 hasAuthorship W2006721081A5051464063 @default.
• W2006721081 hasAuthorship W2006721081A5084753156 @default.
• W2006721081 hasBestOaLocation W20067210811 @default.
• W2006721081 hasConcept C11960822 @default.
• W2006721081 hasConcept C121608353 @default.
• W2006721081 hasConcept C153911025 @default.
• W2006721081 hasConcept C159654299 @default.
• W2006721081 hasConcept C170493617 @default.
• W2006721081 hasConcept C185592680 @default.
• W2006721081 hasConcept C195616568 @default.
• W2006721081 hasConcept C203014093 @default.
• W2006721081 hasConcept C2779786085 @default.
• W2006721081 hasConcept C2781164504 @default.
• W2006721081 hasConcept C530470458 @default.
• W2006721081 hasConcept C542903549 @default.
• W2006721081 hasConcept C54355233 @default.
• W2006721081 hasConcept C553184892 @default.
• W2006721081 hasConcept C55493867 @default.
• W2006721081 hasConcept C86803240 @default.
• W2006721081 hasConcept C95444343 @default.
• W2006721081 hasConceptScore W2006721081C11960822 @default.
• W2006721081 hasConceptScore W2006721081C121608353 @default.
• W2006721081 hasConceptScore W2006721081C153911025 @default.
• W2006721081 hasConceptScore W2006721081C159654299 @default.
• W2006721081 hasConceptScore W2006721081C170493617 @default.
• W2006721081 hasConceptScore W2006721081C185592680 @default.
• W2006721081 hasConceptScore W2006721081C195616568 @default.
• W2006721081 hasConceptScore W2006721081C203014093 @default.

• next